BRIGHT MINDS BIOSCIENCES INC (DRUG) Stock Price, Quote, News and Overview
NASDAQ:DRUG - Nasdaq - CA10919W4056 - Common Stock - Currency: USD
DRUG Quote, Performance and Key Statistics
BRIGHT MINDS BIOSCIENCES INC
NASDAQ:DRUG (1/23/2025, 12:06:46 PM)
32.61
-0.74 (-2.22%)
The current stock price of DRUG is 32.61 USD. In the past month the price decreased by -14.73%. In the past year, price increased by 1646.62%.
DRUG Latest News, Press Releases and Analysis
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE...
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) --...
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
DRUG Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.79 | 299.90B | ||
| AMGN | AMGEN INC | 14.27 | 147.44B | ||
| GILD | GILEAD SCIENCES INC | 20.92 | 115.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 848.92 | 111.50B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.04 | 75.08B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.94B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.17B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.40B | ||
| NTRA | NATERA INC | N/A | 22.58B | ||
| BIIB | BIOGEN INC | 8.7 | 20.69B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.29B |
Related screens
About DRUG
Company Profile
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York and currently employs 0 full-time employees. The company went IPO on 2021-02-08. The firm is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.
Company Info
BRIGHT MINDS BIOSCIENCES INC
19 Vestry Street
New York City NEW YORK US
Employees: 0
Company Website: https://brightmindsbio.com/
Investor Relations: http://brightmindsbio.com/investors/
Phone: 16478658622
DRUG FAQ
What is the price of DRUG?
The current price of DRUG is 32.61 USD.
What is the symbol for BRIGHT MINDS BIOSCIENCES INC?
The exchange symbol of BRIGHT MINDS BIOSCIENCES INC is DRUG and it is listed on the Nasdaq exchange.
On which exchange is DRUG listed?
DRUG is listed on the Nasdaq exchange.
Is DRUG a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for DRUG, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of DRUG.
Does DRUG pay dividends?
DRUG does not pay a dividend.
What is the Price/Earnings (PE) ratio of DRUG?
DRUG does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.64).
What is the Short Interest ratio of DRUG?
The outstanding short interest for DRUG is 3.85% of its float.
DRUG Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DRUG. When comparing the yearly performance of all stocks, DRUG is one of the better performing stocks in the market, outperforming 99.73% of all stocks.
DRUG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DRUG. No worries on liquidiy or solvency for DRUG as it has an excellent financial health rating, but there are worries on the profitability.
DRUG Financial Highlights
Over the last trailing twelve months DRUG reported a non-GAAP Earnings per Share(EPS) of -0.64. The EPS decreased by 65.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.65% | ||
| ROE | -58.31% | ||
| Debt/Equity | 0 |
DRUG Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to DRUG. The Buy consensus is the average rating of analysts ratings from 7 analysts.